摘要目的:分析西妥昔单抗联合mFOLFOX6化疗方案治疗晚期结直肠癌的临床疗效，探讨其对T淋巴细胞亚群分布、患者体能状况、肿瘤标志物水平的影响，并进行安全性分析。方法:选择2020年4月至2022年4月海南省肿瘤医院收治的晚期结直肠癌患者90例，采用随机数字表法将患者随机分为观察组（ n=45）和对照组（ n=45）。对照组采用mFOLFOX6化疗方案治疗，观察组采用西妥昔单抗联合mFOLFOX6化疗方案治疗。比较两组治疗后客观缓解率（ORR）、疾病控制率（DCR）、T淋巴细胞亚群水平（CD3 +、CD4 +、CD8 +占比）、Karnofsky功能状态（KPS）评分、肿瘤标志物血管内皮生长因子（VEGF）、内皮细胞特异分子1（ESM1）、癌胚抗原（CEA）水平及不良反应发生率。 结果:治疗4周期后，观察组ORR为66.67%（30/45），对照组为42.22%（19/45），差异有统计学意义（ χ2=5.42， P=0.020）。观察组DCR为86.67%（39/45），对照组为66.67%（30/45），差异有统计学意义（ χ2=5.03， P=0.025）。观察组T淋巴细胞亚群CD3 +、CD4 +、CD8 +占比分别为（63.35±6.71）%、（35.67±3.96）%、（17.03±2.11）%，对照组分别为（52.23±5.92）%、（30.55±3.51）%、（20.64±2.83）%，观察组CD3 +、CD4 +占比均较对照组高（ t=8.34， P<0.001； t=6.49， P<0.001），CD8 +占比低（ t=6.86， P<0.001）。观察组KPS评分为（95.55±9.74）分，对照组为（85.03±8.92）分，差异有统计学意义（ t=5.34， P<0.001）。观察组VEGF、ESM1、CEA水平分别为（303.45±33.21）ng/L、（75.66±8.36）pg/ml、（7.73±0.98）ng/ml，对照组分别为（364.53±39.07）ng/L、（92.53±9.91）pg/ml、（9.95±1.13）ng/ml，观察组VEGF、ESM1、CEA均较对照组低（ t=7.99， P<0.001； t=8.73， P<0.001； t=9.96， P<0.001）。观察组不良反应总发生率为75.56%（34/45），对照组为66.67%（30/45），差异无统计学意义（ χ2=0.87， P=0.352）。 结论:采用西妥昔单抗联合mFOLFOX6化疗方案治疗晚期结直肠癌患者，临床疗效显著，可改善患者免疫功能，缓解临床症状，调节患者血清肿瘤标志物水平，且不增加不良反应，安全性较好。

abstractsObjective:To analyze the clinical efficacy of cetuximab combined with mFOLFOX6 chemotherapy regimen in the treatment of advanced colorectal cancer, to explore its effects on the distribution of T lymphocyte subsets, patients' physical status and tumor marker levels, and to analyze its safety.Methods:A total of 90 patients with advanced colorectal cancer admitted to the Hainan Cancer Hospital from April 2020 to April 2022 were selected and randomly divided into observation group ( n=45) and control group ( n=45) according to random number table method. The control group was treated with the mFOLFOX6 chemotherapy regimen, while the observation group was treated with cetuximab combined with the mFOLFOX6 chemotherapy regimen. Objective response rate (ORR), disease control rate (DCR), T lymphocyte subsets levels (percentages of CD3 +, CD4 +, CD8 +), Karnofsky performance status (KPS) score, tumor marker vascular endothelial growth factor (VEGF), endothelial cell-specific molecule 1 (ESM1), carcino-embryonic antigen (CEA) levels and the incidence of adverse reactions were compared between the two groups after treatment. Results:After 4 cycles of treatment, the ORR was 66.67% (30/45) in the observation group and 42.22% (19/45) in the control group, and there was a statistically significant difference ( χ2=5.42, P=0.020). The DCR of the observation group was 86.67% (39/45) and that of the control group was 66.67% (30/45), and there was a statistically significant difference ( χ2=5.03, P=0.025). The percentages of T lymphocyte subsets CD3 +, CD4 + and CD8 + in the observation group were (63.35±6.71) %, (35.67±3.96) % and (17.03±2.11) %, respectively, while those in the control group were (52.23±5.92) %, (30.55±3.51) % and (20.64±2.83) %, respectively. The percentages of CD3 + and CD4 + in the observation group were significantly higher than those in the control group ( t=8.34, P<0.001; t=6.49, P<0.001), while the percentage of CD8 + ratio was significantly lower ( t=6.86, P<0.001). The KPS score of the observation group was (95.55±9.74) points, and that of the control group was (85.03±8.92) points, and there was a statistically significant difference ( t=5.34, P<0.001). VEGF, ESM1 and CEA levels in the observation group were (303.45±33.21) ng/L, (75.66±8.36) pg/ml and (7.73±0.98) ng/ml, respectively, while those in the control group were (364.53±39.07) ng/L, (92.53±9.91) pg/ml and (9.95±1.13) ng/ml, respectively. VEGF, ESM1 and CEA levels in observation group were significantly lower compared with control group ( t=7.99, P<0.001; t=8.73, P<0.001; t=9.96, P<0.001). The total incidence of adverse reactions was 75.56% (34/45) in the observation group and 66.67% (30/45) in the control group, and there was no statistically significant difference ( χ2=0.87, P=0.352) . Conclusion:Cetuximab combined with mFOLFOX6 chemotherapy regimen in the treatment of advanced colorectal cancer patients has significant clinical efficacy, can improve the immune function of patients, alleviate clinical symptoms, regulate the level of serum tumor markers in patients without increasing adverse reactions, and has good safety.